Chernov Mikhail F, Nakaya Kotaro, Izawa Masahiro, Hayashi Motohiro, Usuba Yuki, Kato Koichi, Muragaki Yoshihiro, Iseki Hiroshi, Hori Tomokatsu, Takakura Kintomo
Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan.
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1492-8. doi: 10.1016/j.ijrobp.2006.11.023. Epub 2007 Feb 2.
The objective of this retrospective study was evaluation of the outcome after stereotactic radiosurgery (SRS) in patients with intracranial metastases and poor performance status.
Forty consecutive patients with metastatic brain tumors and Karnofsky performance scale (KPS) scores < or =50 (mean, 43 +/- 8; median, 40) treated with SRS were analyzed. Poor performance status was caused by presence of intracranial metastases in 28 cases (70%) and resulted from uncontrolled extracerebral disease in 12 (30%).
Survival after SRS varied from 3 days to 11.5 months (mean, 3.8 +/- 2.9 months; median, 3.3 months). Survival probability constituted 0.50 +/- 0.07 at 3 months and 0.20 +/- 0.05 at 6 months posttreatment. Cause of low KPS score (p = 0.0173) and presence of distant metastases beside the brain (p = 0.0308) showed statistically significant associations with overall survival in multivariate Cox proportional hazards regression analysis. Median survival was 6.0 months if low KPS score was caused by cerebral disease and distant metastases in regions beyond the brain were absent, 3.3 months if low KPS score was caused by cerebral disease and distant metastases in regions beyond the brain were present, and 1.0 month if poor performance status resulted from extracerebral disease.
Identification of the cause of low KPS score (cerebral vs. extracerebral) in patients with metastatic brain tumor(s) may be important for prediction of the outcome after radiosurgical treatment. If poor patient performance status without surgical indications is caused by intracranial tumor(s), SRS may be a reasonable treatment option.
本回顾性研究的目的是评估立体定向放射外科治疗(SRS)颅内转移瘤且身体状况较差患者的治疗结果。
分析了连续40例接受SRS治疗的转移性脑肿瘤患者,其卡诺夫斯基功能状态评分(KPS)≤50(平均43±8;中位数40)。28例(70%)患者身体状况较差是由颅内转移瘤导致,12例(30%)是由脑外疾病未得到控制所致。
SRS后的生存期从3天至11.5个月不等(平均3.8±2.9个月;中位数3.3个月)。治疗后3个月的生存概率为0.50±0.07,6个月时为0.20±0.05。在多因素Cox比例风险回归分析中,低KPS评分的原因(p = 0.0173)和脑外远处转移的存在(p = 0.0308)与总生存期显示出统计学上的显著关联。如果低KPS评分是由脑部疾病导致且脑外区域无远处转移,中位生存期为6.0个月;如果低KPS评分是由脑部疾病导致且脑外区域存在远处转移,中位生存期为3.3个月;如果身体状况较差是由脑外疾病导致,中位生存期为1.0个月。
对于转移性脑肿瘤患者,确定低KPS评分的原因(脑部或脑外)对于预测放射外科治疗后的结果可能很重要。如果无手术指征的患者身体状况较差是由颅内肿瘤导致,SRS可能是一种合理的治疗选择。